569 related articles for article (PubMed ID: 24639191)
21. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
Collins LC; Marotti JD; Gelber S; Cole K; Ruddy K; Kereakoglow S; Brachtel EF; Schapira L; Come SE; Winer EP; Partridge AH
Breast Cancer Res Treat; 2012 Feb; 131(3):1061-6. PubMed ID: 22080245
[TBL] [Abstract][Full Text] [Related]
22. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
23. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
25. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
[TBL] [Abstract][Full Text] [Related]
27. The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.
Lakis S; Kotoula V; Eleftheraki AG; Batistatou A; Bobos M; Koletsa T; Timotheadou E; Chrisafi S; Pentheroudakis G; Koutras A; Zagouri F; Linardou H; Fountzilas G
Breast; 2014 Jun; 23(3):234-43. PubMed ID: 24703723
[TBL] [Abstract][Full Text] [Related]
28. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
29. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
30. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
32. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
33. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
[TBL] [Abstract][Full Text] [Related]
35. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
36. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
Ni YB; Tsang JY; Chan SK; Tse GM
Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
[TBL] [Abstract][Full Text] [Related]
37. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
38. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
[TBL] [Abstract][Full Text] [Related]
39. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
[TBL] [Abstract][Full Text] [Related]
40. Expression of androgen receptors in primary breast cancer.
Park S; Koo J; Park HS; Kim JH; Choi SY; Lee JH; Park BW; Lee KS
Ann Oncol; 2010 Mar; 21(3):488-492. PubMed ID: 19887463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
